Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687377 | 0.93 | AVPR1B (0.71) | AVPR1B | |
| SCHEMBL1687415 | 0.89 | AVPR1B (0.62) | AVPR1B | |
| SCHEMBL1687256 | 0.83 | AVPR1B (0.62) | AVPR1B | |
| SCHEMBL1687423 | 0.83 | AVPR1B (0.74) | AVPR1B | |
| SCHEMBL1687302 | 0.82 | AVPR1B (0.75) | AVPR1B | |
| SCHEMBL1687261 | 0.82 | AVPR1B (0.58) | AVPR1B | |
| SCHEMBL1687365 | 0.81 | AVPR1B (0.59) | AVPR1B | |
| SCHEMBL1687416 | 0.80 | AVPR1B (0.53) | AVPR1B | |
| SCHEMBL1687395 | 0.79 | AVPR1B (0.64) | AVPR1B | |
| SCHEMBL3105263 | 0.79 | AVPR1B (0.83) | AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066640-B1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| EP-2066640-B1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| US-7906504-B2 | N-tert-Butyl-2-[3-(4-fluoro-3-methoxyphenyl)-1-oxo-7-(3-pyrrolidin-1-ylpropoxy)-1H-isoquinolin-2-yl]acetamide; 2-[3-(3-Chlorophenyl)-7-((S)-2-methyl-3-pyrrolidin-1-ylpropoxy)-1-oxo-1H-isoquinolin-2-yl]-N-isopropylacetamide; antidepressants; hypothalamo-pituitary-adrenal axis modulators | N.V. ORGANON (NL) | 2011-03-15 | — | — | US | disclosed |
| US-7906504-B2 | N-tert-Butyl-2-[3-(4-fluoro-3-methoxyphenyl)-1-oxo-7-(3-pyrrolidin-1-ylpropoxy)-1H-isoquinolin-2-yl]acetamide; 2-[3-(3-Chlorophenyl)-7-((S)-2-methyl-3-pyrrolidin-1-ylpropoxy)-1-oxo-1H-isoquinolin-2-yl]-N-isopropylacetamide; antidepressants; hypothalamo-pituitary-adrenal axis modulators | N.V. ORGANON (NL) | 2011-03-15 | — | — | US | disclosed |
| US-7906504-B2 | N-tert-Butyl-2-[3-(4-fluoro-3-methoxyphenyl)-1-oxo-7-(3-pyrrolidin-1-ylpropoxy)-1H-isoquinolin-2-yl]acetamide; 2-[3-(3-Chlorophenyl)-7-((S)-2-methyl-3-pyrrolidin-1-ylpropoxy)-1-oxo-1H-isoquinolin-2-yl]-N-isopropylacetamide; antidepressants; hypothalamo-pituitary-adrenal axis modulators | N.V. ORGANON (NL) | 2011-03-15 | — | — | US | disclosed |
| WO-2008033757-A2 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL) ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-20 | — | — | WO | disclosed |
| US-20080064678-A1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-13 | — | — | US | disclosed |
| US-20080064678-A1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-13 | — | — | US | disclosed |
| US-20080064678-A1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064678-A1 | 2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES | SULT2A1, ACAT2, HDAC6 | AVPR1B 1097/4885SIGMAR1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.